Αρχειοθήκη ιστολογίου

Πέμπτη 14 Δεκεμβρίου 2017

Monoclonal Antibodies Against IL-13 and IL-31RA in Development for Atopic Dermatitis

The IL-13 and IL-31 cytokines and inflammatory pathways have been identified as important for atopic dermatitis (AD) pathophysiology. Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, two phase two trials have been completed with these antibodies in atopic dermatitis treatment. In both trials, significant reductions of Eczema Area and Severity Index (EASI) scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in atopic dermatitis patients.

http://ift.tt/2CmrTKT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου